menu
    • menu
    [{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Third Harmonic Bio Launches to Advance the Next Wave of Medicine for Allergy and Inflammation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Series B Financing","leadProduct":"THB001","moa":"KIT","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0.11,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"Third Harmonic Bio \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Third Harm.."},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$10.9 million","upfrontCash":"Undisclosed","newsHeadline":"Third Harmonic Bio Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"THB001","moa":"KIT","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Third Harmonic Bio \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Third Harm.."},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"THB001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Third Harmonic Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Third Harm.."}]

    Find Clinical Drug Pipeline Developments & Deals by Third Harmonic Bio

    Menu

    Third Harmonic Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Third Harmonic Bio

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Third Harmonic Bio

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THB001

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria

                            Details : The Company is initiating nonclinical studies to elucidate the mechanism for the observed transaminitis, which was not predicted by extensive GLP toxicology studies of THB001 nor observed in the Company’s Phase 1a study.

                            Brand Name : THB001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 15, 2022

                            Lead Product(s) : THB001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Third Harmonic Bio

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Third Harmonic Bio

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THB001

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $10.9 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Third Harmonic Bio Announces Pricing of Upsized Initial Public Offering

                            Details : THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.

                            Brand Name : THB001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 14, 2022

                            Lead Product(s) : THB001

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $10.9 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Third Harmonic Bio

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Third Harmonic Bio

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THB001

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Atlas Venture

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Third Harmonic Bio Launches to Advance the Next Wave of Medicine for Allergy and Inflammation

                            Details : This financing will fund development of the company’s lead candidate, THB001, through the next phase of human studies for the initial indication of chronic urticaria.

                            Brand Name : THB001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 16, 2022

                            Lead Product(s) : THB001

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Atlas Venture

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth